|2.||Interstitial Lung Diseases (Interstitial Lung Disease)
|3.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
|4.||Inclusion Body Myositis
|1.||Kuwana, Masataka: 21 articles (09/2015 - 06/2004)|
|2.||Fujimoto, Manabu: 18 articles (01/2015 - 04/2003)|
|3.||Mimori, Tsuneyo: 17 articles (01/2015 - 09/2004)|
|4.||Lundberg, Ingrid E: 17 articles (11/2014 - 04/2002)|
|5.||Dalakas, Marinos C: 16 articles (02/2015 - 06/2003)|
|6.||Greenberg, Steven A: 15 articles (07/2014 - 06/2004)|
|7.||Werth, Victoria P: 15 articles (07/2012 - 09/2002)|
|8.||Muro, Yoshinao: 13 articles (09/2015 - 09/2010)|
|9.||Miller, Frederick W: 13 articles (09/2014 - 07/2002)|
|10.||Casciola-Rosen, Livia: 12 articles (12/2015 - 09/2002)|
|1.||Intravenous Immunoglobulins (IVIG)FDA Link
11/01/1995 - "We describe a group of patients with dermatomyositis, resistant to available therapies, whose muscle strength, skin changes, and muscle biopsies improved significantly during treatment with intravenous immune globulin. "
12/30/1993 - "High-dose intravenous immune globulin is a safe and effective treatment for refractory dermatomyositis."
01/01/2000 - "IVIG is effective in selected dermatomyositis patients. "
05/01/1996 - "In a double-blind, placebo-controlled study, using objective criteria for improvement, IVIG demonstrated moderate to dramatic improvement in 75% of the patients with dermatomyositis. "
09/01/2014 - "Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease."
01/01/1995 - "[Dermatomyositis: successful therapy with high dosage intravenous 7S immunoglobulins]."
07/01/2014 - "Intravenous immunoglobulin infusion is a costly treatment option that is reserved in the presence of refractory dermatomyositis based on a trial showing superior efficacy against control in patients with impaired swallowing or with contraindications to immunosuppressive drugs. "
11/01/2000 - "Intravenous immunoglobulin is not only effective for the cutaneous complications of dermatomyositis but has been helpful in other extramuscular manifestations."
01/01/2007 - "Although only a minority of these indications (dermatomyositis, Kawasaki's disease) are officially registered or based on double-blind, placebo-controlled clinical studies, the observed efficacy and safety profile of currently available intravenous immunoglobulin sometimes makes this a treatment of choice for initiation of therapy or for replacement of more toxic alternatives, such as systemic immunosuppressive medications. "
08/01/2015 - "He had been diagnosed with common variable immune deficiency (CVID) and dermatomyositis at the age of 50 and was started on immunoglobulin (Ig) replacement therapy shortly after diagnosis. "
|3.||Adrenal Cortex Hormones (Corticosteroids)IBA
12/01/2004 - "The dermatomyositis remitted without oral corticosteroids in 2 months, and the remission had continued for 6 years. "
01/01/1999 - "The diagnostic work up for an underlying disease was negative and the histologic examination confirmed the diagnosis of dermatomyositis, which subsequently improved with corticosteroids."
02/01/1977 - "Modern treatment of childhood dermatomyositis with corticosteroids has resulted in greatly improved prognosis and style of life. "
01/01/1977 - "The present revision has been carried out in order to final out to what extent corticosteroids have improved the vital and functional prognosis of dermatomyositis. "
09/01/2015 - "She was maintained on corticosteroids to manage her dermatomyositis. "
|4.||Cyclosporine (Ciclosporin)FDA LinkGeneric
01/01/2012 - "We report a case of cyclosporine-induced haemolytic anaemia in a 9-year-old girl being treated for severe dermatomyositis."
12/01/2006 - "Cyclosporine A as treatment of esophageal involvement in dermatomyositis."
09/01/2001 - "Cyclosporin A in treatment of refractory adult polymyositis/dermatomyositis."
12/01/2000 - "To evaluate the efficacy and toxicity of cyclosporin A (CSA) in the treatment of refractory adult polymyositis/dermatomyositis (PM/DM). "
12/01/2000 - "Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review."
|5.||Methotrexate (Mexate)FDA LinkGeneric
01/01/1997 - "Low-dose oral methotrexate administered weekly is effective in treatment of the cutaneous manifestations of dermatomyositis and frequently enables a reduction or discontinuation of corticosteroid therapy."
01/01/1997 - "Our purpose was to determine whether low-dose methotrexate administered weekly in combination with other systemic therapies or as a sole systemic agent is effective in the treatment of the cutaneous disease in patients with dermatomyositis. "
05/01/1995 - "Although methotrexate is an effective treatment for dermatomyositis, side effects are common. "
03/01/2012 - "Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions."
06/01/2013 - "Methotrexate for the treatment of cutaneous dermatomyositis."
|6.||Tacrolimus (Prograf)FDA LinkGeneric
01/01/2004 - "The results of this brief observational study using topical tacrolimus ointment for the treatment of refractory cutaneous lesions of dermatomyositis are encouraging. "
01/01/2004 - "To study the treatment of patients with refractory cutaneous lesions of dermatomyositis using topical tacrolimus 0.1% ointment. "
01/01/2012 - "Coadministration of tacrolimus with corticosteroid accelerates recovery in refractory patients with polymyositis/ dermatomyositis: a retrospective study."
10/01/2006 - "Topical tacrolimus seems to be a good therapeutic alternative for resistant skin lesions of dermatomyositis. "
10/01/2006 - "We report here the case of three patients presenting resistant cutaneous lesions of dermatomyositis successfully treated with topical tacrolimus. "
|7.||rituximab (Mabthera)FDA Link
06/01/2008 - "This case documented the benefit of the rituximab-SRL combination to treat PTLD while maintaining dermatomyositis in remission."
06/01/2007 - "An open-label trial of rituximab therapy was conducted in 8 adult patients with dermatomyositis. "
06/01/2007 - "A pilot trial of rituximab in the treatment of patients with dermatomyositis."
06/01/2012 - "Rituximab as a first-line agent for the treatment of dermatomyositis."
12/01/2011 - "Rituximab and mycophenolate combination therapy in refractory dermatomyositis with multiple autoimmune disorders."
|8.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/01/2015 - "We report a 37 years old male with a dermatomyositis treated with oral cyclophosphamide. "
06/01/2013 - "In this cohort of polymyositis/dermatomyositis, treatment with IV pulse cyclophosphamide was associated with improvement; the therapeutic response was sustained in majority of the patients."
07/01/2011 - "[Effective cyclophosphamide pulse therapy for an young infant with severe dermatomyositis]."
09/01/1992 - "[Minipulses of cyclophosphamide in the treatment of dermatopolymyositis with lung involvement]."
01/01/2007 - "To study the efficacy and safety of monthly intravenous pulse cyclophosphamide (IVCYC) therapy for progressive interstitial pneumonia in polymyositis/dermatomyositis (PM/DM). "
|9.||Prednisolone (Predate)FDA LinkGeneric
01/01/2014 - "On examination she had features diagnostic of dermatomyositis and she was started on prednisolone. "
01/01/2014 - "Both parameters decreased in association with prednisolone tapering, whereas dermatomyositis subsequently recurred and the administration of glucocorticoid therapy was repeated. "
07/01/1998 - "She was diagnosed as having dermatomyositis and was initially treated with prednisolone. "
01/01/1986 - "High-dose intravenous methyl-prednisolone in chronic polymyositis/dermatomyositis."
11/01/1987 - "A complete remission of the dermatomyositis and the paralysis of the radial nerve were achieved within months with prednisolone medication and physiotherapy; the peroneus nerve paralysis improved only slightly. "
07/01/1953 - "[Anatomoclinical and metabolic modifications in a case of dermatomyositis apparently cured by cortisone]."
06/01/1955 - "[Clinical aspects and cortisone therapy of dermatomyositis]."
04/01/1954 - "[Successful cortisone therapy of dermatomyositis]."
01/01/1954 - "[Subacute dermatomyositis and necrotic capillaritis with rapid fatal evolution; failure of cortisone]."
03/01/1953 - "[Fatal acute dermatomyositis; failure of cortisone therapy]."
05/10/2011 - "The serum levels of IFNα and IFNβ decreased significantly after treatment in 12 PM/DM (polymyositis/dermatomyositis) patients (P < 0.01). "
07/01/1999 - "We experienced a case with dermatomyositis who developed multiple subcutaneous nodules after treatment with MTX. "
07/01/1997 - "The characteristic findings of pulmonary involvement in polymyositis (PM) or dermatomyositis (DM) and the change in findings before and after treatment were evaluated with sequential high-resolution CT studies. "
09/01/2013 - "Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis."
01/01/2012 - "To investigate peripheral blood lymphocyte subpopulations, particularly helper T (Th) cells and cytokine expression before and after treatment in polymyositis (PM) and dermatomyositis (DM). "
|2.||Drug Therapy (Chemotherapy)
01/01/2015 - "Although initial chemotherapy led to regression, the dermatomyositis developed an independent course with new pathological changes leading to the progression of the disease. "
11/01/2008 - "Dermatomyositis induced by drug therapy: a review of case reports."
01/01/1995 - "We report a 68-year-old man who had developed dermatomyositis after ten years of chemotherapy for CLL. "
01/01/2015 - "Then chemotherapy and radiotherapy were applied, and oral corticoid associated with immunosupressive drug was administered for dermatomyositis control. "
03/01/2015 - "Moreover, dermatomyositis or polymyositis onset during pregnancy or the postpartum period had good outcome after drug therapy."
01/01/2014 - "Dermatomyositis in a kidney transplant patient: a case report."
06/01/2008 - "Forty-three patients (4-18 years) with renal glomerular diseases, dermatomyositis, inflammatory bowel disease, juvenile rheumatoid arthritis, post-solid organ transplant, and Duchenne muscular dystrophy were studied. "
12/01/2003 - "As a relatively well-tolerated immunosuppressive used in organ transplant recipients, MMF has recently been reported to show promise for several dermatologic conditions, including psoriasis, pemphigus vulgaris, pyoderma gangrenosum, bullous lichen planus, and even connective tissue diseases such as lupus erythematosus and dermatomyositis. "
01/01/2008 - "Besides the classical inflammatory myopathies (IM), dermatomyositis (DM), polymyositis, and inclusion body myositis, the much larger spectrum of IM includes focal and nodular myositis, granulomatous myositis, macrophagic myofasciitis, graft vs. host myositis, eosinophilic myositis, and other immune-associated conditions, some of them only recently described. "
12/01/2005 - "Since the early 1980s, the therapeutic efficacy of IVIg has been established in idiopathic thrombocytopenic purpura, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, dermatomyositis and Kawasaki syndrome, and the prevention of graft versus host disease in recipients of allogeneic bone marrow transplants. "
|4.||Mesenchymal Stem Cell Transplantation
07/01/2011 - "To assess the safety and clinical efficacy of allogeneic mesenchymal stem cell transplantation (MSCT) in a small-scale pilot study with 10 patients with drug-resistant polymyositis (PM) or dermatomyositis (DM). "
07/01/2011 - "Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis."
11/01/2011 - "Pilot studies suggest efficacy of alemtuzumab in inclusion body myositis and allogeneic mesenchymal stem cell transplantation in polymyositis/dermatomyositis. "
01/01/2014 - "Our aim was to evaluate the safety and efficacy of a low-intensity resistance training program combined with partial blow flow restriction (BFR training) in a cohort of patients with polymyositis (PM) and dermatomyositis (DM). "
03/01/2012 - "For patients with polymyositis and dermatomyositis a few studies have reported reduced clinical disease activity after resistance training in patients with chronic phase of disease. "
01/01/2014 - "Safety and possible effects of low-intensity resistance training associated with partial blood flow restriction in polymyositis and dermatomyositis."
06/15/2007 - "Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis."
01/01/2013 - "The risk of bias of the strength training trial in myotonic dystrophy and the aerobic exercise trial in polymyositis and dermatomyositis was judged as uncertain, and for the combined strength training and aerobic exercise trial, the risk of bias was judged as adequate. "